In all, __number__ patients with advanced disease ( __number__ squamous cell carcinoma and seven adenocarcinoma) received oral capecitabine ( __number__ mg m( __number__ ) twice daily on days __number__ ) plus intravenous docetaxel ( __number__ mg m( __number__ ) on day __number__ ) every __number__ weeks as first- (n = __number__ ) or second-line (n = __number__ ) therapy.